Zobrazeno 1 - 10
of 89
pro vyhledávání: '"M. de Boer-Dennert"'
Autor:
N. van Zandwijk, M. J. van den Bent, Jaap Verweij, A.S.Th. Planting, M. de Boer-Dennert, A. van der Gaast, Jan H.M. Schellens, Marc Maliepaard, Elisabeth Brouwer, M.E.L. van der Burg, J. Ma
Publikováno v:
British Journal of Cancer
British Journal of Cancer, 88, 814-821. Nature Publishing Group
British Journal of Cancer, 88, 814-821. Nature Publishing Group
The objective of this phase II and pharmacologic study was to explore the feasibility, toxicity and activity of adaptive intrapatient dose escalation of cisplatin in a dose-intensive weekly schedule using predefined levels of exposure, with the ultim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78d542e326d573ab138f25fa71a5de59
https://doi.org/10.1038/sj.bjc.6600794
https://doi.org/10.1038/sj.bjc.6600794
Autor:
A de Vos, Marc Maliepaard, Jaap Verweij, M de Boer Dennert, J. Ma, Jan H.M. Schellens, A. S. T. Planting
Publikováno v:
Anti-Cancer Drugs, 12, 667-675. Lippincott Williams & Wilkins
The purpose of this study was to explore the feasibility and toxicity of intrapatient dose adjustment using predefined levels of exposure to cisplatin, with the ultimate goal to further improve the antitumor activity of the treatment. The primary par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aa7fefc150be3bbc9c85eed5b8e0f9f
https://doi.org/10.1097/00001813-200109000-00004
https://doi.org/10.1097/00001813-200109000-00004
Autor:
G. J. Creemers, M. de Boer-Dennert, M. Harteveld, J.H.M. Schellens, Jaap Verweij, P. Wissel, S. Depee, J. F. Pritchard, A. S. T. Planting, C. J. H. Gerrits
Publikováno v:
British Journal of Cancer
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally. Patients with a histo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::409550a72cd6ecccec82a3dcf901dc9c
https://doi.org/10.1038/bjc.1997.490
https://doi.org/10.1038/bjc.1997.490
Autor:
M.E.L. van der Burg, A. van der Gaast, M. J. van den Bent, J.H.M. Schellens, H Goey, G. Stoter, A. S. T. Planting, Jaap Verweij, S Kho, M. de Boer-Dennert
Publikováno v:
Cancer Chemotherapy & Pharmacology, 40, 347-352. Springer-Verlag
As a dose-response relationship has been suggested for cisplatin, it appeared attractive to explore high-dose-intensity regimens in non-small-cell lung cancer. In a phase I study of weekly administration of cisplatin combined with oral etoposide we a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf20c6ec29c53ea8979429a45f02295d
https://doi.org/10.1007/s002800050668
https://doi.org/10.1007/s002800050668
Autor:
R. de Wit, J.H.M. Schellens, Jaap Verweij, O. van Tellingen, M. de Boer-Dennert, J. H. Beijnen
Publikováno v:
British Journal of Cancer
We investigated the pharmacokinetic profile and the efficacy of ondansetron (day 1) given as 16 mg suppository once a day, as compared with ondansetron 8 mg tablets twice daily, in patients receiving moderately emetogenic chemotherapy. The study was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86fcc622406491bf2671d63d06da82d
https://doi.org/10.1038/bjc.1996.361
https://doi.org/10.1038/bjc.1996.361
Autor:
Jaap Verweij, M.E.L. van der Burg, G. Stoter, J. Ma, E. van Meerten, A. S. T. Planting, J.H.M. Schellens, Paul I.M. Schmitz, M. de Boer-Dennert
Publikováno v:
British Journal of Cancer
The study was designed to investigate possible relationships between tumour response and exposure to cisplatin (area under the curve of unbound cisplatin in plasma, AUC) and DNA-adduct formation in leucocytes (WBC) in patients with solid tumours. Pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9fdfd6c19cca4092b99ed9c2fa16f13
https://doi.org/10.1038/bjc.1996.296
https://doi.org/10.1038/bjc.1996.296
Autor:
Hilde Rosing, G. J. Creemers, Jan H.M. Schellens, M. De Boer-Dennert, M. Mcdonald, J. H. Beijnen, Jaap Verweij, B.E. Davies
Publikováno v:
British Journal of Cancer
The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan (SKF 104864-A) when administered as a chronic treatment. We determined the apparent bioavailability and pharmacokinetics of topotecan administered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b9fa9e427e2b9251e5cef8284216399
https://doi.org/10.1038/bjc.1996.243
https://doi.org/10.1038/bjc.1996.243
Autor:
G. J. Creemers, K. Selinger, P. Wissel, Jaap Verweij, A. S. T. Planting, C. J. H. Gerrits, Y. Marijnen, R. Kunka, M. Harteveld, M. de Boer-Dennert, J.H.M. Schellens
Publikováno v:
British Journal of Cancer
Topoisomerase I inhibitors are interesting anti-cancer agents with a novel mechanism of action. We performed a phase I study with intravenous GI147211, a new semisynthetic camptothecin analogue, using a daily x 5 schedule administered every 3 weeks,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1457abcb27b05b975b3c471ac928a1a7
https://doi.org/10.1038/bjc.1996.130
https://doi.org/10.1038/bjc.1996.130
Autor:
Laurence J. C. van Warmerdam, Hilde Rosing, Jaap Verweij, Robert A. A. Maes, Maureen M. de Boer-Dennert, Jos H. Beijnen, B.E. Davies, Jan H.M. Schellens
Publikováno v:
Cancer Chemotherapy and Pharmacology. 35:237-245
Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::978cc7652ae5fea4f3ae6e3d93d91608
https://doi.org/10.1007/bf00686554
https://doi.org/10.1007/bf00686554
Autor:
A. S. T. Planting, H H Hansen, Hilde Rosing, B Lund, I. Koier, Jos H. Beijnen, Jaap Verweij, M de Boer-Dennert
Publikováno v:
Annals of Oncology. 4:673-678
Purpose A phase I study with topotecan (SKF 104864-A, NSC 609699), a semisynthetic analog of camptothecin, was performed using a daily-times-5 regimen, given i.v. q 3 weeks, to evaluate the pharmacokinetics and toxicities of the compound. Patients an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d36ef072e9d6550dec2fd2078c6f00ff
https://doi.org/10.1093/oxfordjournals.annonc.a058623
https://doi.org/10.1093/oxfordjournals.annonc.a058623